MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)

This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.

开始日期2024-11-22

申办/合作机构

Intellia Therapeutics, Inc.

[+1]

NCT06128629

/ Suspended临床3期

MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

开始日期2023-12-13

申办/合作机构

Intellia Therapeutics, Inc.

[+1]

NCT04601051

/ Completed临床1期

Phase 1 Two-Part (Open-label, Single Ascending Dose (Part 1) and Open-label, Single Dose Expansion (Part 2)) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NTLA-2001 in participants with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM) or wild type cardiomyopathy (ATTRwt-CM)

开始日期2020-11-05

申办/合作机构

Intellia Therapeutics, Inc.

100 项与 Nexiguran ziclumeran 相关的临床结果

登录后查看更多信息

100 项与 Nexiguran ziclumeran 相关的转化医学

登录后查看更多信息

100 项与 Nexiguran ziclumeran 相关的专利（医药）

登录后查看更多信息

项与 Nexiguran ziclumeran 相关的文献（医药）

2026-01-05·EUROPEAN HEART JOURNAL

Transthyretin amyloid cardiomyopathy: from cause to novel treatments

Review

作者: Fontana, Marianna ; Aimo, Alberto ; Porcari, Aldostefano ; Gillmore, Julian D ; Hawkins, Philip N ; Emdin, Michele ; Solomon, Scott D

Abstract:

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disorder marked by amyloid deposition in the heart, ultimately impairing cardiac function. Recent treatment advances have paralleled an evolving understanding of ATTR-CM pathophysiology. One emerging hypothesis suggests that an imbalance between in vivo amyloid production and natural clearance may drive disease progression, a conceptual framework that still requires validation. Transthyretin (TTR) stabilizers, such as tafamidis and acoramidis, mitigate amyloid formation by promoting the native tetrameric conformation of circulating TTR, thereby slowing functional decline and prolonging survival. Similarly, TTR gene silencers inhibit hepatic TTR synthesis, and gene-editing therapy with nexiguran ziclumeran offers an additional strategy to reduce amyloid production. However, these approaches do not enhance the body’s limited capacity to clear existing amyloid deposits, underscoring the need for novel agents that accelerate amyloid removal. Promisingly, monoclonal antibodies targeting TTR amyloid are under development, with early clinical trials suggesting that this passive immunotherapy may reverse disease progression and improve heart function. Ultimately, optimal management of ATTR-CM will require further elucidation of the complex interplay between amyloid formation, its structural and functional impacts, its clearance mechanisms, and the potential for myocardial reverse remodelling.

2025-12-01·Current heart failure reports

Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions

Review

作者: Morfino, Paolo ; Emdin, Michele ; Vergaro, Giuseppe ; Chubuchna, Olena ; Aimo, Alberto ; Castiglione, Vincenzo ; Buda, Gabriele ; Ferrari Chen, Yu Fu ; Fabiani, Iacopo

Abstract:

Purpose of Review:

Cardiac amyloidosis (CA) is a condition caused by interstitial infiltration of misfolded proteins structured into amyloid fibrils. Transthyretin (ATTR) and immunoglobulin light chain (AL) amyloidosis represent the most common forms of CA. CA was traditionally perceived as a rare and incurable disease, but diagnostic and therapeutic advances have undermined the conventional paradigm.

Recent Findings:

The standard of care for ATTR-CA include agents capable of selectively stabilizing the precursor protein (e.g., tafamidis), whereas the plasma cell clone is the main target of chemotherapy for AL-CA. For long, tafamidis represented the only drug approved for patients with ATTR-CA. Recent data from ATTRibute-CM led to the approval of acoramidis, whereas patisiran received refusal based on the APOLLO-B trial. Novel CRISPR-Cas9-based drugs (i.e., NTLA-2001) hold great potential in the setting of ATTR-CA. Several hematological regimens are available to treat AL-CA. The main limit of current therapies is their inability to trigger removal of amyloid from tissues. However, the investigation of monoclonal antibodies targeting misfolded ATTR (e.g., PRX004, NI301A) or AL (e.g., birtamimab, anselamimab) has led to encouraging results.

Summary:

Various cutting-edge strategies are being tested for treatment of CA and may change the prognostic landscape of this condition in the next years.

2025-10-09·NEW ENGLAND JOURNAL OF MEDICINE

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy

Article

作者: Xu, Yuanxin ; Lebwohl, David ; Gane, Ed ; Smith, Derek ; Shahda, Safi ; Sonderfan, Alison ; Haagensen, Alexandra ; Kachadourian, Jessica ; Adams, David ; Kao, Justin ; Litchy, William ; Manvelian, Garen ; Ward, Jonathan H. ; Täubel, Jörg ; Gutstein, David E. ; Echaniz-Laguna, Andoni ; Gillmore, Julian D. ; Walsh, Liron ; Leung, Adia ; Zhu, Peijuan ; Pilebro, Björn

BACKGROUND:

Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a rare, multisystem, progressive, debilitating, and fatal disease characterized by tissue deposition of misfolded transthyretin (TTR) in peripheral nerves. Nexiguran ziclumeran (nex-z) is an investigational in vivo therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease) that is designed to reduce serum TTR levels through selective inactivation of TTR in the liver.

METHODS:

In this phase 1, open-label study, we administered one infusion of nex-z to patients with ATTRv-PN. Primary objectives included assessment of the safety and pharmacodynamics of nex-z. Secondary end points included changes in the familial amyloid polyneuropathy stage, polyneuropathy disability score, serum neurofilament light chain (NfL) level, modified body-mass index (modified BMI, defined as the conventional BMI [weight in kilograms divided by square of height in meters] multiplied by the albumin level in grams per liter), and modified Neuropathy Impairment Score+7 (mNIS+7; range, 0 to 304, with higher scores indicating more impairment).

RESULTS:

A total of 36 patients received nex-z; the mean follow-up was 27 months. The mean percent change from baseline in the serum TTR level was -90% at day 28, which was sustained through month 24 (-92%). Treatment-related adverse events included transient infusion-related reactions (in 21 patients), decreased thyroxine level without hypothyroidism or elevated thyrotropin level (in 8), and headache (in 4). One participant died from cardiac amyloidosis, and one withdrew owing to progressive decline in motor function. Serious adverse events were reported in 11 patients. At month 24, the familial amyloid polyneuropathy stage and polyneuropathy disability score remained stable in 29 and 27 patients, respectively; improved in 2 and 5, respectively; and worsened in 2 and 2, respectively. The mean change in the serum NfL level was -9.0 pg per milliliter, and the change in the modified BMI was 24.7. The mean change from baseline in the mNIS+7 was -8.5.

CONCLUSIONS:

A single administration of nex-z in patients with ATTRv-PN was associated with rapid, deep, and durable reductions in serum TTR levels. The results support further investigation of nex-z to treat ATTRv-PN. (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).

430

项与 Nexiguran ziclumeran 相关的新闻（医药）

2026-09-08

·全球GCT研究

递送无万能解：AAV、LNP与EV谁主沉浮？

2025年5月全球首例个体化碱基编辑新生儿(LNP递送)诞生突破;同期Elevidys(AAV)因致死性肝损伤被FDA加黑框警告;EV基因递送仍在I期艰难回答安全/效力/CMC——同一时间窗,突破、危机与不确定并存——Nature Biomedical Engineering 2026(Lee/Jiang/Kim)发表迄今最全面的AAV/LNP/EV横向比较——货物兼容性/胞内逃逸/免疫耐受性三条分界线如何决定平台命运;LNP"肝脏王者+肝外困局"、EV"屏障穿越者+CMC困局"、融合策略与开放问题——深度拆解基因递送的工程哲学之争一、引言:突破、危机与不确定并存的一个时间窗基因递送平台正在经历一个"冰火同炉"的时间窗:2025年5月,一名患有氨甲酰磷酸合成酶1(CPS1)缺乏症的新生儿接受了全球首例个体化碱基编辑治疗——递送载体是脂质纳米颗粒(LNP)——这是Penn Medicine/NIH支持的历史性突破,婴儿KJ的故事让"一次编辑、改写命运"从概念变成病历[6][7];然而仅仅一个月后,Elevidys(AAV基因疗法)的安全事件持续发酵:致命性肝损伤报告将这款DMD疗法推至FDA监管审查中心,2025年11月FDA批准其黑框警告并限制适应症[2][3][4];与此同时,细胞外囊泡(EV)基因递送仍在临床早期艰难推进——多项I期还在回答安全性、有效性与CMC可控性这些"基础问题"[1][8]。三个平台,同一个时间窗:LNP站在突破的聚光灯下,AAV被危机的阴影笼罩,EV在不确定中缓慢爬坡——它们不是在一条赛道上竞争,而是在三组根本变量上错位[1]。近日,得克萨斯大学安德森癌症中心Betty Y. S. Kim、姜文与北京大学深圳研究生院Andrew S. Lee等人在《Nature Biomedical Engineering》发表系统综述"Engineering challenges and translational opportunities in emerging gene delivery platforms",对AAV、LNP与EV三大平台做了迄今最全面的横向比较——廓清了每个平台真实的边界与局限[1]。如果你是一名患者或家属:递送平台决定基因治疗的"最后一公里"——理解AAV/LNP/EV的差异,能帮你看懂"为什么有的基因药要入脑注射、有的只需静脉输注"[1]。如果你是一名临床医生:递送平台的免疫原性与组织分布直接决定安全性监测方案(Elevidys教训:AAV需要严密肝功监测)——平台选择是临床风险管理的上游变量[1][2]。如果你在biotech新药研发:这是2026年递送领域最重要的一份"地图"——平台选择决定能装什么货物、能到哪个器官、能激起多少免疫反应——选错平台,再好的治疗基因也到不了该去的地方[1]。二、综述坐标:谁写的、比较了什么综述的基本盘:(1)出处——Nature Biomedical Engineering 2026(Lee A.S./Jiang W./Kim B.Y.S.等)——Nature子刊+工程学与转化医学交叉定位,是递送领域最有分量的综述平台之一[1];(2)团队——MD Anderson(Betty Y. S. Kim)+北京大学深圳研究生院(Andrew S. Lee)——临床转化视角(肿瘤)+工程学视角(纳米递送)的交叉组合[1];(3)范围——AAV(病毒载体代表)/LNP(合成纳米颗粒代表)/EV(生物纳米囊泡代表)三大平台——"迄今最全面的横向比较"——不是各讲各的故事,而是同一张表上的头对头分析[1];(4)核心框架——三组根本变量:能装什么(货物兼容性)、能到哪里(组织分布)、进去以后能不能真正表达(胞内递送/逃逸)——外加贯穿始终的免疫耐受性维度[1];(5)产业价值——这篇综述出现在碱基编辑器已走进新生儿病房、体内CAR-T开启首批临床试验的时代——递送平台的选择,正直接决定哪些疾病能率先走到患者面前[1][6][7]。图1|三大平台的根本变量错位:四条分界线 · 查看原文三、分界线一:货物兼容性——平台选择最底层的约束第一个分界线问的是:"你的治疗货物,这个平台装得下吗?"(1)AAV的载量天花板清晰——约4.7kb的单链DNA——直接把DMD全长基因(约2.4Mb,但微型/迷你基因可行)、碱基编辑器、先导编辑器挡在门外——双载体系统、迷你基因等补救方案一直在优化,但公认代价是转导效率下滑、生产成本上升、异常转基因产物风险增加[1];(2)LNP几乎没有严格的尺寸天花板——临床优化LNP对1-5kb mRNA的封装效率超过90%;自扩增RNA(saRNA,9-12kb)也能达70-90%——这种灵活性是LNP在COVID疫苗后持续拓宽应用边界的底层逻辑[1];(3)EV的问题不在尺寸而在装载效率——天然EV主要携带小型非编码RNA,对全长mRNA的装载量极低:每个囊泡约1-10个拷贝——即使辅以电穿孔,封装效率也很少超过30%,与LNP形成数量级的落差——这个数字从根本上限制了EV在mRNA系统性递送中的可行性,也解释了为何当前EV临床试验仍集中在较窄适应症[1];(4)产业含义——选平台先看货物:小基因(酶/因子)三平台都可;大基因编辑系统(碱基/先导编辑器)基本锁定LNP(或双AAV的妥协);这是"货物决定平台"的第一原则[1]。四、分界线二:胞内逃逸——所有非病毒系统长期未跨过的坎第二个分界线问的是:"进入细胞后,货物真的能到作用位置吗?"(1)LNP的逃逸困境——进入细胞后,大多数LNP被运送至溶酶体降解——内体逃逸比例仅约1-2%——即使LNP高效完成mRNA封装,绝大多数货物在到达核糖体前就已失活[1];(2)EV的内在优势——通过磷脂酰丝氨酸与四跨膜蛋白介导的膜融合,EV的内体逃逸率约20%,显著高于LNP——胰腺癌模型对比:EV溶酶体滞留率5.7% vs LNP 26%;仅用LNP十分之一RNA剂量,EV实现更强肿瘤抑制与更长生存;吸入给药场景EV递送IL-12 mRNA的蛋白表达约为脂质体的2.2倍[1];(3)但数据必须放回上下文——EV的高逃逸建立在极低装载量基础上;LNP即便逃逸效率低下,凭借远胜EV的货物数量,蛋白表达总量仍能维持竞争力——人促红细胞生成素mRNA对照:等剂量RNA下MC3-LNP表达比EV高6-8倍——两个指标必须合看,不可孤立解读[1];(4)工程学启示——"逃逸效率"与"货物数量"是乘数关系——EV要赢,必须在装载量上缩小差距;LNP要赢,必须在逃逸率上突破1-2%的天花板——双方都在补自己的短板[1]。五、分界线三:免疫耐受性——近些年争议最大的维度第三个分界线问的是:"身体会怎么对待这个外来者?"(1)AAV的预存免疫问题突出——AAV1/2血清阳性率60-80%——直接影响转导效率,并将大量患者排除在临床试验外;高剂量全身给药可诱发T细胞介导肝毒性与补体驱动微血管病变——Elevidys安全事件再次将这一隐患推至前台(2025.11 FDA黑框警告:急性肝损伤/肝衰竭死亡报告;限制为可行走DMD患者;Sarepta已更新标签含ALI/ALF黑框警告)[1][2][3][4][5];(2)LNP的"好记录"与"隐忧"并存——COVID疫苗时代建立良好安全性记录——但PEG化脂质可能诱发抗PEG抗体,限制重复给药;IVT mRNA及saRNA残留dsRNA副产物可激活天然免疫(TLR7/8)——疫苗场景可接受,在基因编辑或再生医学中则更棘手——核苷修饰+严格dsRNA去除工艺已显著降低已获批产品风险,但在编辑/再生医学/高频重复给药场景仍需单独评估[1];(3)EV的低免疫原性植根于内源起源——理念上最贴近生物相容性理想——EV递送I型胶原α1 mRNA的局部炎症显著低于MC3-LNP;VEGF-A递送中EV引发的细胞因子释放与免疫激活最少——但EV免疫原性高度依赖供体细胞来源/纯化方法/工程化步骤,支撑系统性判断的数据仍相当有限[1];(4)监管视角——免疫耐受性决定"能不能重复给药"——AAV(预存抗体)基本单次;LNP(抗PEG)受限重复;EV(理论低免疫)可能支持重复——这是平台在慢性病/需要多次给药场景的分水岭[1]。六、LNP的临床现实:肝脏的王者,肝外的困局 LNP的临床成熟度在三平台中无可争议地最高——但它的疆域高度集中:(1)已建立的地位——Onpattro 2018年获批;COVID mRNA疫苗验证全球规模生产可扩展性[1];(2)体内基因编辑的"身份跃迁"——近年来最引人注目的数据:NTLA-2001单次静脉输注后转甲状腺素蛋白(TTR)降幅达96%;NTLA-2002在遗传性血管性水肿实现超85%蛋白敲降、几乎所有患者达无发作状态;CD117-LNP递送腺嘌呤碱基编辑器修正镰状细胞病β-珠蛋白突变,在长期重建细胞中实现48%编辑效率——这些数字标志LNP正从mRNA递送工具向基因编辑核心载体完成实质性跃迁[1];(3)肝外递送的系统性短板——静脉注射后约90%的LNP在1小时内被肝脏摄取;选择性器官靶向(SORT等)通过调整脂质组分改变器官分布,在肺/脾等取得临床前验证,但临床数据远不及肝脏深厚;内体逃逸1-2%的天花板难以单靠配方微调根本突破[1];(4)下一代工程方向——新一代可离子化脂质、pH响应性融合肽、proton sponge类添加剂的组合策略在推进;近期一种基于正高斯曲率fusogenic cubosomes的方法实现10分钟内接近100%的mRNA装载与更高效膜融合——可能构成LNP工程化的下一个关键节点[1];(5)定位判断——肝脏代谢病/血液病(经肝编辑)/疫苗是LNP的"已证领土";CNS/肌肉/肿瘤微环境等肝外场景仍是"待开发边疆"——"肝脏王者"是荣耀,也是天花板[1]。七、EV:生物屏障的穿越者,但离临床仍有一段距离 EV的差异化价值与转化困境——综述给出的"冷静画像":(1)穿越屏障的独特能力——对血脑屏障的穿透力、天然低免疫原性、内在组织归巢倾向——让EV在中枢神经系统疾病、肺部疾病与眼科疾病等"难以抵达"适应症中拥有真实而鲜活的差异化价值[1];(2)对比数据——双靶向EV在胰腺癌模型中肿瘤积聚量达LNP的2-3倍;心脏祖细胞来源EV经肌肉注射后,心脏局部mRNA递送比例达56%,而LNP仅19%[1];(3)转化被两个未系统解决的问题拖住——①生产均一性与可扩展性:EV天然异质性使批次一致性极难保证;GMP级纯化在产率与纯度间取舍无统一答案,现有方法产率波动在5%-60%之间;②监管路径模糊:尚无专门针对EV基因疗法的监管框架——天然EV/工程化EV/负载外源货物的EV在监管分类上仍存歧义[1];(4)典型案例——综述提及:Capricor Therapeutics的CAP-1002(心球来源、具EV富集属性的DMD治疗候选物)因有效性不足与CMC问题遭FDA拒绝——成为EV类疗法临床转化不确定性的标志性案例[1];(5)定位判断——EV的"临床前故事"诱人(屏障穿越+低免疫+归巢),但"临床现实"骨感(I期仍在回答安全/效力/CMC)——EV是"潜力股",兑现期取决于CMC工程能否解决均一性与规模化[1]。八、融合策略:不是非此即彼,而是相互借力图2|融合策略:不是非此即彼,而是相互借力 · 查看原文综述中最具产业参考价值的部分——跨平台杂合策略:(1)LNP/EV包裹AAV(杂合病毒-非病毒)——通过脂质膜遮蔽衣壳表位,降低中和抗体识别率、提高血清稳定性——EV-AAV6/9构建体在免疫动物模型中的心脏转导效率达单独AAV的两倍以上,肺部模型同样明显改善——工程难点:共包装效率偏低(传统AAV生产方式对EV相关AAV的富集效率不足20%),需额外引入分离纯化步骤[1];(2)EV-LNP杂合——尝试将LNP的高载量能力与EV的天然靶向性/低免疫原性黏合——多通过冻融/超声/挤出/PEG诱导膜融合组装——核心挑战:融合过程中的货物泄漏与粒子聚集[1];(3)fusogenic cubosomes(最具吸引力的推进)——前述正高斯曲率立方体方法:10分钟内近100%装载+高效膜融合——同时回应"装载"与"逃逸"两个核心瓶颈[1];(4)底层逻辑——没有一个平台是万能的——将各平台互补优势组装到一起,可能比在单一平台上极限工程优化更有效——"杂合"是工程哲学从"单点极致"到"系统整合"的跃迁[1]。九、开放问题:头对头匮乏与患者个体差异综述在结论部分点出的两个"不容回避"的现实:(1)头对头比较极度匮乏——关于三个平台的头对头研究至今极少;已有对比研究中不少存在控制变量不等效(剂量不匹配、配方优化程度不对等),结论可推广性打折扣——这不仅是学术问题:当"选LNP还是EV"得不到标准化头对头数据支撑时,研发决策就容易被先入为主的平台偏好左右[1];(2)患者个体差异被系统性忽视——年龄、性别、代谢状态、免疫状态都会显著影响LNP的生物分布与表达水平——现有临床研究对这些变量的系统记录远远不够;年龄对LNP吞噬清除效率的影响已有直接证据,性别差异对纳米医学效能的扰动也有初步数据——这些变量不是背景噪声,而是决定疗法在真实人群中能否起效的关键参数[1];(3)对行业的提醒——①建立标准化的跨平台比较框架(统一剂量/配方优化基准);②临床试验纳入年龄/性别/代谢/免疫的分层分析——"精准递送"不仅要选对平台,还要选对人群[1]。十、研发决策启示:怎么选平台——一张决策清单把综述的横向比较转化为研发决策清单——六步选型法:(1)看货物——货物>4.7kb或含编辑系统→优先LNP(或双AAV妥协);小型治疗基因→三平台皆可,再看其他维度[1];(2)看靶器官——肝脏→LNP是王者(NTLA数据背书);CNS/眼/肌肉→AAV血清型成熟或EV的屏障穿越;肺/心脏局部→EV展示优势(心脏56% vs LNP 19%)[1];(3)看给药次数——单次给药(遗传病根治)→AAV/LNP皆可;需要重复给药(慢病/疫苗加强)→EV理论优势+LNP抗PEG限制需评估[1];(4)看免疫背景——患者预存AAV抗体(60-80%人群阳性)→AAV排除或需杂合策略;dsRNA/先天免疫敏感场景→严格工艺+LNP修饰或EV[1];(5)看CMC现实——LNP制造最成熟(COVID验证);AAV产能紧张但路径清晰;EV的均一性(产率5-60%)与监管分类是最大不确定——临床时间表要计入CMC风险[1];(6)看监管与时间窗——EV无专门监管框架→与FDA早期沟通成本高;杂合策略分类更模糊——"成熟平台快上市、新平台赌未来"的组合策略常见于头部公司[1]。十一、给各方建议(三类读者全覆盖)11.1 给患者与家庭 (1)基因治疗新闻中的"载体"决定体验:AAV疗法(Elevidys等)需要严密肝功监测与激素预处理;LNP疗法多为静脉输注、可重复;EV疗法仍在早期——参与试验前问清平台类型与对应监测要求[1][2];(2)CPS1新生儿KJ的个性化碱基编辑是真实突破,但那是"一人一药"的极端定制——不要把它当作普遍可及的治疗预期[6][7]。11.2 给临床医生 (1)平台决定监测方案——AAV(Elevidys黑框警告后:每周肝功监测+急性肝损伤识别)、LNP(输注反应/抗PEG相关重复给药评估)、EV(理论低免疫但仍需数据)——把"载体类型"纳入安全性管理框架[1][2];(2)注意患者个体差异(年龄/性别/代谢/免疫状态)对递送效率的影响——未来精准递送可能需要按人群分层选择平台[1];(3)关注杂合策略(如EV-AAV)临床试验——它们的免疫背景要求可能与纯AAV不同[1]。11.3 给biotech/投资者 (1)平台选型是战略问题——用"货物×靶器官×给药次数×免疫背景×CMC×监管"六维决策清单做尽调——避免"先入为主的平台偏好"(综述点名的行业通病)[1];(2)跟踪三大信号——①fusogenic cubosomes等新一代LNP逃逸技术(若突破1-2%天花板,LNP疆域将大幅扩张);②EV的CMC均一性解决方案(决定EV能否走出I期泥潭);③杂合策略的共包装效率改善(>20%是门槛)[1];(3)风险纪律——EV/杂合平台的监管模糊性是真实折价因素;AAV平台需计入"预存抗体排除患者+黑框警告类事件"的商用风险;LNP平台需盯住肝外递送进展——没有万能平台,也没有永远的平台冠军——押注平台时要买"工程改进的期权"而非"现状的线性外推"[1][2][3]。十二、结语:三种工程哲学的博弈基因递送的平台之争,说到底,是不同工程哲学之间的博弈:AAV依赖生物识别的精确性(病毒亿万年的进化产物),LNP信奉化学成分的可调性(人类合成化学的极致),EV追求内源仿生的兼容性(向细胞自己借运输工具)——三者都有不容忽视的临床价值,也都有尚未触及根基的核心局限[1]。这篇Nature Biomedical Engineering综述的珍贵之处,不在"褒贬",而在"定位":它把每个平台的边界画得清清楚楚——AAV的载量墙、LNP的逃逸墙与肝脏墙、EV的装载墙与CMC墙——并指出翻墙的两条路:单平台极限工程(如fusogenic cubosomes),或跨平台杂合组装(如EV-AAV)——"没有一个平台是万能的",这句朴素判断,可能是2026年递送领域最重要的行业共识[1]。对一个碱基编辑器已经走进新生儿病房、CAR-T体内编程正在开启首批临床试验的时代:递送平台的选择,将直接决定哪些疾病能够率先走到患者面前——AAV的精确、LNP的可调、EV的仿生,不是三选一,而是三道门——聪明的开发者,会为每种疾病找到它该走的那扇门[1][6][7]。希望加入“全球GCT行业交流群”的读者，请加以下二维码联系工作人员 10月20日北京将举办2026CGT创新药出海BD战略大会，感兴趣的读者可以点击专言，公众号：全球GCT研究10月20日北京CGT新药出海BD全维度战略分享会参考文献 [1]Nature Biomedical Engineering(2026):Lee A.S./Jiang W./Kim B.Y.S.等——Engineering challenges and translational opportunities in emerging gene delivery platforms——AAV/LNP/EV三大平台最全面横向比较:货物兼容性(AAV 4.7kb/LNP 90%封装/EV 1-10拷贝)/胞内逃逸(LNP 1-2%/EV 20%)/免疫耐受(AAV预存60-80%/LNP抗PEG与dsRNA/EV内源低免疫)/LNP肝脏王者(NTLA-2001 TTR 96%)与肝外困局(90%入肝)/EV屏障穿越与CMC产率5-60%及监管模糊(Capricor CAP-1002案例)/fusogenic cubosomes/杂合策略/头对头匮乏与患者个体差异 · Nature Biomedical Engineering(2026,顶刊综述) [2]FDA官方(2025.11.14):FDA Approves New Safety Warning and Revised Indication that Limits Use for Elevidys Following Reports of Fatal Liver Injury——ELEVIDYS黑框警告(急性肝损伤/肝衰竭风险)+限制适应症;每周肝功监测 · FDA官方(2025.11.14) [3]Reuters(2025.11.14):US FDA adds strongest warning to Sarepta Elevidys after fatal liver injuries——最严重安全警告+限制为可行走DMD患者 · Reuters(权威媒体) [4]CureDuchenne/Sarepta官方(2025-2026):Elevidys非卧床患者商业使用暂停(急性肝衰竭死亡病例后);2025.11黑框警告+限制标签;增强免疫抑制方案试验 · CureDuchenne(患者组织)/Sarepta官方 [5]Sarepta官方IR(2025-2026):ELEVIDYS标签更新(急性严重肝损伤ALI与急性肝衰竭ALF黑框警告) · Sarepta官方IR [6]NUCDF/Penn Medicine(2025-2026):Baby KJ——CPS1缺乏症新生儿2025年成为首个接受个性化CRISPR基因编辑治疗的患者(NIH支持/Penn Medicine) · NUCDF患者组织/Penn Medicine [7]EMJ Reviews(2026):Personalised CRISPR Therapy Success in Baby With Rare Disorder——CPS1缺乏症婴儿个体化碱基编辑治疗的早期代谢改善 · EMJ Reviews(医学媒体)[8]MDPI Cells(2026,引录综述出处):Lee/Jiang/Kim综述被引记录——Emerging Roles of Extracellular Vesicle-Mediated Transfer(出处确认) · MDPI Cells(出处互证)

2026-09-04

·allsci.com

Intellia secures USD 400m non-dilutive debt facility ahead of lonvo-z commercial launch

Massachusetts-based Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced a non-dilutive senior secured term loan facility of up to USD 400 million with OrbiMed, structured to fund the commercial launch of its lead CRISPR gene editing therapy and advance its second late-stage program without shareholder dilution. The timing is directly tied to lonvoguran ziclumeran (lonvo-z), whose rolling biologics license application (BLA) to the US FDA is underway following positive Phase III data, with a US launch targeted for H1 2027. The facility is structured in tranches over a five-year term. USD 75 million was funded at closing. Five additional tranches totaling up to USD 225 million are drawable at Intellia's option, subject to achievement of specified milestones linked primarily to lonvo-z. A further USD 100 million is available subject to mutual agreement between the parties. OrbiMed, a healthcare-focused investment firm, is the sole lender. Intellia raised around USD 180 million in a public equity offering earlier this year to extend its runway. The OrbiMed facility supplements that equity base with non-dilutive debt timed to commercial readiness activities. Lonvo-z is an in vivo CRISPR/Cas9 therapy designed to permanently reduce plasma kallikrein by inactivating the KLKB1 gene via a single outpatient infusion, targeting hereditary angioedema (HAE) Types I and II. The Phase III HAELO trial reported an 87% reduction in mean monthly HAE attacks versus placebo at the primary endpoint, with full data showing a 91% reduction in moderate and severe attacks published in the New England Journal of Medicine in 2026. Intellia said the BLA rolling submission is expected to be completed in H2 2026. The second program, nexiguran ziclumeran (nex-z), a single-dose TTR gene-editing therapy for transthyretin amyloidosis, has resumed enrollment in its Phase III MAGNITUDE (cardiomyopathy) and MAGNITUDE-2 (polyneuropathy) trials after FDA clinical holds were lifted in early 2026; Intellia's CFO cited nex-z advancement as a secondary use of the facility's flexibility. The deal reflects a broader trend among late-stage biotech companies using milestone-linked debt to extend financing flexibility ahead of potential product launches. For Intellia, USD 225 million of the additional facility is tied primarily to lonvo-z milestones, while a further USD 100 million remains available subject to mutual agreement. The structure gives the company access to additional capital as lonvo-z approaches a potential 2027 launch while limiting the need for near-term equity issuance. Access the AllSci platform to explore the science behind the news. Spot something wrong? Report an issue with this article

临床3期基因疗法

2026-09-04

·BioSpace

Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million

$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed, a leading global healthcare investment firm. The transaction provides Intellia with greater financial and operational flexibility as it advances toward several key milestones, including a planned U.S. approval and commercial launch of lonvoguran ziclumeran (lonvo-z) as a one-time treatment for patients with hereditary angioedema (HAE). “Lonvo-z has the potential to transform the treatment paradigm for people living with HAE as well as the future capital needs of our company,” said Edward Dulac, Intellia’s Chief Financial Officer. “This non-dilutive financing enables us to more freely execute our plan to successfully launch lonvo-z in HAE, advance nexiguran ziclumeran through multiple important milestones in transthyretin amyloidosis and create value through our early pipeline development efforts.” “OrbiMed is proud to partner with Intellia Therapeutics, a well-recognized leader in the in vivo gene editing revolution,” said Matthew Rizzo, General Partner at OrbiMed. “We are looking forward to supporting the team as it approaches a number of exciting and transformational milestones.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); The facility includes an initial term loan of $75 million that was funded at closing; 5 additional tranches totaling up to $225 million that can be drawn at Intellia’s option subject to its achievement of specified milestones related primarily to lonvo-z; and an additional $100 million available subject to mutual agreement between the parties during the five-year term of the agreement. Additional details of the loan agreement will be filed with the Securities and Exchange Commission on a Current Report on Form 8-K. TD Cowen acted as exclusive financial advisor to Intellia on the transaction. Goodwin Procter LLP acted as legal advisor to Intellia. Covington & Burling LLP acted as legal advisor to OrbiMed. About Lonvo-z Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 ( KLKB1 ) gene with a single dose that is administered in an outpatient setting. Lonvo-z has received five notable regulatory designations: Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia Therapeutics ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx . Forward-Looking Statements This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: the expected benefits of the senior secured term loan facility, including the extent to which the facility may provide Intellia with financial, operational and strategic flexibility and enable Intellia to execute its plans and advance its programs through anticipated value inflection points; Intellia’s ability to achieve the applicable milestones and satisfy the other conditions required to access the additional $225 million under the facility; the availability of an additional $100 million subject to mutual agreement between the parties; the success and advancement of its program for lonvoguran ziclumeran or “lonvo-z” (formerly known as NTLA-2002) for the treatment of hereditary angioedema (“HAE”), including its expectations regarding review and approval of the biologics license application for lonvo-z, its ability to successfully launch lonvo-z in HAE, its belief that lonvo-z has the potential to transform the treatment paradigm for people living with HAE as well as the Company’s future capital needs, lonvo-z’s potential to become the first one-time treatment for HAE, and the potential for lonvo-z to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene following a single dose; its ability to advance nexiguran ziclumeran or "nex-z" (formerly known as NTLA-2001) through multiple important milestones in transthyretin amyloidosis; and its ability to create value through its early pipeline development efforts. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to achieve the applicable milestones and satisfy the other conditions required to access additional tranches under the loan facility; the possibility that Intellia and OrbiMed will not mutually agree to make the additional $100 million available; risks associated with Intellia’s indebtedness, including its debt-service obligations, restrictive covenants, security interests and the potential for default; the possibility that the loan facility will not provide the anticipated financial, operational or strategic flexibility or enable Intellia to execute its plans as expected; uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z and nex-z, including risks related to the ability to develop and successfully commercialize lonvo-z or any of Intellia’s product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; and risks related to the potential delay of planned clinical trials or regulatory filings due to regulatory feedback or other developments. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its recent quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. ezstandalone.cmd.push(function () { ezstandalone.showAds(133); }); Investor Contact: Jason Fredette Vice President, Investor Relations and Corporate Communications Intellia Therapeutics, Inc. jason.fredette@intelliatx.com Media Contact: Mike Tattory Vice President LifeSci Communications mtattory@lifescicomms.com

100 项与 Nexiguran ziclumeran 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑神经疾病	临床3期	阿根廷	Intellia Therapeutics, Inc.	2024-11-22
脑神经疾病	临床3期	巴西	Intellia Therapeutics, Inc.	2024-11-22
脑神经疾病	临床3期	墨西哥	Intellia Therapeutics, Inc.	2024-11-22
脑神经疾病	临床3期	新加坡	Intellia Therapeutics, Inc.	2024-11-22
脑神经疾病	临床3期	中国台湾	Intellia Therapeutics, Inc.	2024-11-22
脑神经疾病	临床3期	泰国	Intellia Therapeutics, Inc.	2024-11-22
神经肌肉疾病	临床3期	阿根廷	Intellia Therapeutics, Inc.	2024-11-22
神经肌肉疾病	临床3期	巴西	Intellia Therapeutics, Inc.	2024-11-22
神经肌肉疾病	临床3期	墨西哥	Intellia Therapeutics, Inc.	2024-11-22
神经肌肉疾病	临床3期	新加坡	Intellia Therapeutics, Inc.	2024-11-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04601051 (Pubmed \| N Engl J Med)	临床1期	转甲状腺素蛋白相关家族性淀粉样多神经病变	36	Nexiguran Ziclumeran	積艱醖鏇壓襯鹽選壓襯(簾壓顧壓築遞膚鬱顧蓋) = 衊糧衊齋遞夢簾齋鬱遞範憲餘選鹹膚繭築襯糧 (夢餘鏇鬱築齋廠鑰積顧 ) 更多	积极	2025-10-09
NCT04601051 (Company_Website 1 \| Company_Website 2) 人工标引	临床1期	转甲状腺素蛋白相关家族性淀粉样多神经病变	36	Nexiguran ZiclumeranNexiguran Ziclumeran (nex-z) (Dose-escalation portion)	製夢鑰夢築願壓鹽構餘(膚餘壓遞選鹹鑰鬱鹽膚) = 繭夢壓獵窪鬱觸窪製繭壓壓膚齋鹽顧積範艱鹽 (構鑰範範窪夢淵繭憲鑰 ) 更多	积极	2025-05-18
NCT04601051 (Company_Website 1 \| Company_Website 2) 人工标引	临床1期	转甲状腺素蛋白相关家族性淀粉样多神经病变	36	Nexiguran ZiclumeranNexiguran Ziclumeran (nex-z) (Dose expansion portion)	夢範遞築艱鏇網襯憲醖(鹹築廠膚蓋壓鬱積鬱製) = 顧淵簾鹽繭鑰憲窪選齋壓觸網鹹夢鑰鏇網艱鬱 (鏇蓋蓋蓋餘願鹹齋鹹糧, 10.2) 更多	积极	2025-05-18
NCT04601051 (Phase 1, Pubmed \| N Engl J Med)	临床1期	心肌疾病 serum TTR level \| N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels \| high-sensitivity cardiac troponin T levels	36	Nexiguran Ziclumeran (Nex-Z)	糧獵繭醖衊顧鬱壓顧夢(憲積築簾範願膚築蓋鑰) = 遞繭簾艱憲膚艱積鬱獵鏇壓膚憲觸簾獵構範構 (膚築積齋憲鑰製憲襯構, -33 ~ 49) 更多	积极	2024-12-12
NCT04601051 (Literature) 人工标引	临床1期	转甲状腺素蛋白淀粉样变性心肌病	36	Nexiguran ziclumeran (nex-z)	醖窪獵醖窪獵膚繭鑰廠(餘構鬱齋願鬱鏇製簾蓋) = 積願觸鏇製壓顧膚願範觸構遞願簾餘壓簾膚簾 (築構襯簾壓願憲簾獵蓋, -33 ~ 49) 更多	积极	2024-11-16
NCT04601051 (Biospace) 人工标引	临床1期	遗传性转甲状腺素蛋白淀粉样变性	62	NTLA-2001	餘鹹淵夢鹹構顧襯築鹹(襯鹹廠顧壓選選簾糧鏇) = The most commonly reported adverse events were infusion-related reactions, which occurred in 38% of patients. The majority of adverse events, including infusion-related reactions, were Grade 1 or 2 in severity, transient and resolved spontaneously. Other adverse events that were reported in greater than 10% of patients included headache, diarrhea and back pain, and were all Grade 1 or 2. 鏇願鏇襯憲觸醖鏇範願 (觸淵餘衊窪遞窪簾鹹衊 ) 更多	积极	2023-11-02
NCT04601051 (NTLA-2001, EASL2022)	临床1期	遗传性转甲状腺素蛋白淀粉样变性 TTR protein	14	NTLA-2001 0.3 mg/kg	窪鬱選鏇構願艱獵窪窪(觸築鏇選憲蓋鏇齋鹽範) = Mild and transient infusion reactions were the most common adverse event with NTLA-2001 齋遞遞糧鏇餘艱簾鏇餘 (鹽製衊淵醖夢鹹鹹鏇簾 )	积极	2022-06-24
NCT04601051 (Pubmed 1 \| Pubmed 2 \| Br Dent J \| N Engl J Med) 人工标引	临床1期	遗传性转甲状腺素蛋白淀粉样变性	6	NTLA-2001 (0.1 mg / kg)	範襯衊窪遞觸網糧夢觸(觸鹹餘願鹽壓艱衊膚夢) = 築繭窪繭願壓鑰鑰製願鬱壓獵蓋繭獵簾淵窪餘 (膚鏇蓋蓋構鏇鬱糧艱淵 )	积极	2021-08-05
	临床1期	遗传性转甲状腺素蛋白淀粉样变性	6	NTLA-2001 (0.3 mg / kg)	範襯衊窪遞觸網糧夢觸(觸鹹餘願鹽壓艱衊膚夢) = 範壓簾齋窪襯鹽膚鏇艱鬱壓獵蓋繭獵簾淵窪餘 (膚鏇蓋蓋構鏇鬱糧艱淵 )	积极	2021-08-05